PRAGUE-18 trial: Prasugrel and ticagrelor: Equally safe and effective in STEMI

(European Society of Cardiology) The antiplatelet drugs prasugrel and ticagrelor had similar safety and efficacy among patients with acute myocardial infarction and ST segment elevations (STEMI), according to results of PRAGUE-18, the first randomized, head-to-head comparison of the drugs.